Switch theme
Sign up to access all valuation multiples
Peptron Inc is a biotechnology company engaged in developing fundamental technologies for peptide-based medicines. Its technology includes PeptrEX and SmartDepot. PeptrEX is an automatic system, enabling to synthesize simultaneously from a few to hundred types of peptides. SmartDepot is a proprietary ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of the drug. The group’s research and development products include Luphere Depot for the treatment of prostate cancer and endometriosis, SR Exenatide PT302 AND SR EXENATIDE PT304 for the treatment of type II diabetes, SR Exenatide PT320 and 330 for the treatment of Parkinson’s and Alzheimer’s disease and SR Octreotide for the treatment of acromegaly and carcinoid tumor.
1997
n/a
Last FY Revenue $2.3M
Last FY EBITDA -$13.4M
$3.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Peptron achieved revenue of $2.3M and an EBITDA of -$13.4M.
Peptron expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Peptron valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $2.3M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.8M | XXX | XXX | XXX |
| Gross Margin | XXX | 35% | XXX | XXX | XXX |
| EBITDA | XXX | -$13.4M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -585% | XXX | XXX | XXX |
| EBIT | XXX | -$12.0M | XXX | XXX | XXX |
| EBIT Margin | XXX | -524% | XXX | XXX | XXX |
| Net Profit | XXX | -$16.0M | XXX | XXX | XXX |
| Net Margin | XXX | -699% | XXX | XXX | XXX |
| Net Debt | XXX | $5.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Peptron's stock price is KRW 232500 (or $169).
Peptron has current market cap of KRW 5.40T (or $3.9B), and EV of KRW 5.29T (or $3.8B).
See Peptron trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.8B | $3.9B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Peptron has market cap of $3.9B and EV of $3.8B.
Peptron's trades at 1679.2x EV/Revenue multiple, and -286.8x EV/EBITDA.
Equity research analysts estimate Peptron's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Peptron's P/E ratio is not available.
See valuation multiples for Peptron and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.9B | XXX | $3.9B | XXX | XXX | XXX |
| EV (current) | $3.8B | XXX | $3.8B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 1679.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -286.8x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -320.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -245.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -354.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPeptron's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Peptron's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Peptron's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Peptron and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -585% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 37% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 385% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 559% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Peptron acquired XXX companies to date.
Last acquisition by Peptron was XXXXXXXX, XXXXX XXXXX XXXXXX . Peptron acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Peptron founded? | Peptron was founded in 1997. |
| Where is Peptron headquartered? | Peptron is headquartered in South Korea. |
| Who is the CEO of Peptron? | Peptron's CEO is Mr. Ho-Il Choi. |
| Is Peptron publicy listed? | Yes, Peptron is a public company listed on KRX. |
| What is the stock symbol of Peptron? | Peptron trades under 087010 ticker. |
| When did Peptron go public? | Peptron went public in 2015. |
| Who are competitors of Peptron? | Similar companies to Peptron include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Peptron? | Peptron's current market cap is $3.9B |
| Is Peptron profitable? | Yes, Peptron is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
